摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acid N-methyl-D-glucamine salt

中文名称
——
中文别名
——
英文名称
5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acid N-methyl-D-glucamine salt
英文别名
4-[[4-[2-(4-butylphenyl)ethynyl]phenyl]methyl-hexylcarbamoyl]-2-carboxyphenolate;methyl-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]azanium
5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acid N-methyl-D-glucamine salt化学式
CAS
——
化学式
C7H17NO5*C33H37NO4
mdl
——
分子量
706.877
InChiKey
XTRLMSHIKBMPQU-WZTVWXICSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    51
  • 可旋转键数:
    20
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    191
  • 氢给体数:
    8
  • 氢受体数:
    10

反应信息

  • 作为产物:
    描述:
    5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acidN-甲基-D-葡胺甲醇 为溶剂, 以to give 103 mg of the title compound as a white powder的产率得到5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acid N-methyl-D-glucamine salt
    参考文献:
    名称:
    1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors
    摘要:
    本发明涉及公式(I)的羧酸及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱,包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合症(PCOS)。特别地,本发明涉及使用公式(I)的羧酸来调节,尤其是抑制PTP的活性。
    公开号:
    US07947851B2
点击查看最新优质反应信息

文献信息

  • [EN] 1,1'-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS<br/>[FR] DERIVES DE 1,1'-(1,2-ETHYNEDIYLE)BIS-BENZENE INHIBITEURS DE PTP 1-B
    申请人:APPLIED RESEARCH SYSTEMS
    公开号:WO2005097773A1
    公开(公告)日:2005-10-20
    The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.
    本发明涉及式(I)的羧酸及其用于治疗和/或预防肥胖和/或由胰岛素抵抗或高血糖介导的代谢紊乱的使用,包括I型和/或II型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合征(PCOS)。特别是,本发明涉及使用式(I)的羧酸来调节,尤其是抑制PTPs的活性。
  • 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors
    申请人:Swinnen Dominique
    公开号:US20090029903A1
    公开(公告)日:2009-01-29
    The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.
    本发明涉及式(I)的羧酸及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱,包括糖尿病I型和/或II型、不良葡萄糖耐受性、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合征(PCOS)。特别地,本发明涉及使用式(I)的羧酸调节,尤其是抑制PTP活性。
  • US7947851B2
    申请人:——
    公开号:US7947851B2
    公开(公告)日:2011-05-24
  • 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors
    申请人:Merck Serono SA
    公开号:US07947851B2
    公开(公告)日:2011-05-24
    The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.
    本发明涉及公式(I)的羧酸及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱,包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合症(PCOS)。特别地,本发明涉及使用公式(I)的羧酸来调节,尤其是抑制PTP的活性。
查看更多